Multi-Omics Insights Driving Personalized Therapy in Metastatic Triple-Negative Breast Cancer (TNBC)
November 11, 2025
Patient: 55 years – Female with metastatic triple-negative breast carcinoma (ER–, PR–, HER2 1+) Clinical Testing:Alterations: TP53 (p.D281E), MSH3 (p.R454*), PIK3CA (p.E542K),